Report Code: A10447 | Pages: NA | Mar 2023 | 1460 Views | ||
Author(s) : NA | Tables: NA | Charts: NA |
|
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Gram-positive Bacterial Infections Market
Request Now !Bacteria is a class of micro-organisms that play an important role in the development of various infectious disease to the human being and animal kingdom. Bacteria classified on the basis of gram staining test. It is divided into two different types, such as gram-positive bacteria and gram-negative bacteria. Gram-positive bacteria have cell wall composed of thick layers peptidoglycan. Gram-positive bacteria are rod shapes, they're known as bacilli. These bacteria are present on the skin, sometime it cause serious medical conditions. This bacteria observed as violet purple colored stains which give the positive result in the gram stain test. It is observed under microscope.
Gram-positive bacteria responsible for infecting humans and animals with variety of acute and chronic diseases. These bacteria causes various infectious diseases such as MRSA, pneumonia, sepsis, sinusitis, cellulitis, otitis, pharyngitis, impetigo, etc. For the treatment of this infection diseases various antibiotic and antifungal drugs are introduce in the gram positive infectious market such as B-Lactam, quinolones, macrolides, tetracycline, aminoglycosides, sulphonamides and phenicols. Gram-positive bacterial infection drugs kill the gram-positive bacterial infections including MRSA infections, sinusitis, and pneumonia. These drugs act by various mechanisms such as inhibition of cell wall synthesis, inhibition of protein biosynthesis, and inhibition of DNA replication.
Market scope and structure analysis:
Report Metric | Details |
Market size available for years | 2020–2027 |
Base year considered | 2019 |
Forecast period | 2021–2027 |
Forecast units | Value ($USD) |
Segments covered | Drug type, Disease, Route of Administration |
Region covered | North America (U.S., and Canada), Europe (U.K., Germany, and Rest of Europe), Asia-Pacific (China, India, Japan, and Rest of Asia-Pacific), LANTAM (Brazil, Mexico, and Rest of Latin America), Middle East & Africa (South Africa Saudi Arabia, UAE) |
Companies covered | Major players analyzed include, Basilea Pharmaceuticals Ltd., Cubist Pharmaceuticals, Novabiotics Ltd., TAXIS Pharmaceuticals, Inc., Aphios Corporation, Pfizer, Inc., GSK plc, Theravance, Inc. Bayer AG, Sanofi, Merck & Co., Inc., AstraZeneca, Theravance Biopharma, Bristol-Myers Squibb Company, Novartis AG, and Allergan plc. |
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.
Recently, ongoing outbreak of COVID-19 impacted on gram positive bacterial infection market. Covid-19 started as a cluster of pneumonia cases with an unknown cause. The cause of the pneumonia was found to be a new virus. Severe Acute Respiratory Syndrome Coronavirus 2. The novel coronavirus belongs to the family of Coronaviridae and genus beta coronavirus, comprising vertebrate respiratory viruses including HCoV-OC43, responsible for 10% cases of common cold. Recently there is no availability of effective gram positive infection drug in the market that help to kill the corona virus. Various pharmaceutical companies’ of scientist, researcher undertaken initiative to develop the drug product that permanently kill the coronavirus.
Globally, North America and Europe are the most dominating markets due to the increasing incidence of various gram-positive bacterial infections, and presence of major market player. However, Asia-Pacific are expected to show profitable growth due to increasing occurrence of diseases, increasing awareness amongst the population about the diseases caused by gram-positive bacteria and their chronic effects.
As per the WHO report, in 2018, around 1.3 million people is died due to the tuberculosis, it is the second greatest killer across the globe. For the treatment of bacterial infectious disease various schemes are introduce by the WHO, which includes “DOTS” and “Stop TB Strategy” (particular for tuberculosis), which helps in growing awareness amongst the population, that drive the growth of the market.
The factors such as Growing incidence of various gram positive bacterial infections, increasing R&D activities, increasing awareness about infectious diseases rising investment in healthcare, rapidly increasing in antibacterial resistance, rising government initiatives, increasing investment in R&D activities, newer bacterial infection treatment and infection control in healthcare settings are majorly drive the growth of gram positive bacterial infection market. However, the factors that restrain the growth of gram positive bacterial infection such as stringent government regulation, high cost of treatment and R&D, ignorance towards the symptoms, etc.
Major Key market manufacturer have been focusing on producing new product solution for specific applications as there are varying demands based on the utilization. Leading market players have determined how improved accuracy can be influential in many applications. Recently the product available in the market to treat gram positive bacterial infection include LTX-109, PYN-6, RX-P792, XF-70, and TD-1607, etc.
In 2019, “Basilea” get a positive results of phase 3 TARGET study with antibiotic “Ceftobiprole”. This drug used for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
In 2019, “Bayer” has launched natural dipeptide antibiotic TAN 1057 AB which shows outstanding antibacterial activity against staphylococci including methicillin resistant Staphylococcus aureus.
In 2019, AstraZeneca get approval from USFDA for the pivotal Phase III studies of “RECLAIM-1 and RECLAIM-2”, drug product which investigating the potential of the antibiotic ceftazidime-avibactam (CAZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections.
Key segments covered:
Segments | Sub-segments |
Drug Type |
|
Disease |
|
Route of Administration |
|
Key benefits of the report:
Questions answered in the Gram-Positive Bacterial Infections Market research report:
Gram-positive Bacterial Infections Market: Global Opportunity Analysis and Industry Forecast, 2020–2027 Report Highlights
Aspects | Details |
---|---|
By Drug Type |
|
By Disease |
|
By Route of Administration |
|
By Region |
|
Key Market Players | Basilea Pharmaceuticals Ltd., Cubist Pharmaceuticals, Novabiotics Ltd., TAXIS Pharmaceuticals, Inc., Aphios Corporation, Pfizer, Inc., GSK plc., Theravance, Inc., Bayer AG, Sanofi |
Loading Table Of Content...
Start reading.
This Report and over 19,667+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers